REG-Syncona Limited: Publication of 2018 Annual Report and Notice of AGM

SynconaAnnouncement

27/06/2018 07:05

Syncona Limited

Publication of 2018 Annual Report and Notice of Annual General Meeting

27 June 2018

Syncona Limited (“Syncona”), a leading healthcare company focused on
investing in and building global leaders in life science, today announces that
it has published its Annual Report and Accounts for the year ended 31 March
2018 (“2018 Annual Report”). In addition, Syncona has published its Notice
of Annual General Meeting 2018 and a circular relating to the 2018 Dividend.

In compliance with Listing Rule 9.6.1, these documents have today been
submitted to the National Storage Mechanism and will shortly be available for
inspection at www.morningstar.co.uk/uk/nsm.

Copies of these documents, together with the Form of Proxy for use in
connection with the 2018 Annual General Meeting, Charitable Allocation Form
and Cash Election Form, are available electronically on Syncona’s website at
www.synconaltd.com/investor-relations. Printed copies of these documents are
also being posted to shareholders where requested.

Syncona’s Annual General Meeting will be held at 10:30am on 31 July 2018 at
the offices of Northern Trust International Fund Administration Services
(Guernsey) Limited, Trafalgar Court, Les Banques, St Peter Port, Guernsey GY1
3QL.

 ENDS 

Enquiries

Syncona Ltd
Siobhan Weaver / Annabel Clay
Tel: +44 (0) 20 7611 2031

Copies of this press release and other corporate information can be found on
the company website at: www.synconaltd.com  

About Syncona:

Syncona is a leading FTSE250 healthcare company focused on investing in and
building global leaders in life science. Our vision is to deliver
transformational treatments to patients in truly innovative areas of
healthcare while generating superior returns for shareholders.

We seek to partner with the best, brightest and most ambitious minds in
science to build globally competitive businesses.

We take a long-term view, underpinned by a deep pool of capital, and are
established leaders in the development of genetic medicine, particularly gene
and cell therapy. We focus on delivering dramatic efficacy for patients in
areas of high unmet need.



Copyright (c) 2018 PR Newswire Association,LLC. All Rights Reserved